[go: up one dir, main page]

EP2718293A1 - Pyridopyrazines substituées en tant que nouveaux inhibiteurs de syk - Google Patents

Pyridopyrazines substituées en tant que nouveaux inhibiteurs de syk

Info

Publication number
EP2718293A1
EP2718293A1 EP12797167.9A EP12797167A EP2718293A1 EP 2718293 A1 EP2718293 A1 EP 2718293A1 EP 12797167 A EP12797167 A EP 12797167A EP 2718293 A1 EP2718293 A1 EP 2718293A1
Authority
EP
European Patent Office
Prior art keywords
optionally substituted
cycloalkyi
heterocycle
halo
substituted lower
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12797167.9A
Other languages
German (de)
English (en)
Other versions
EP2718293B1 (fr
EP2718293A4 (fr
Inventor
Wei-Guo Su
Wei Deng
Jianguo Ji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hutchmed Ltd
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2718293(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to HRP20180139TT priority Critical patent/HRP20180139T1/hr
Priority to SI201231176T priority patent/SI2718293T1/en
Priority to SM20180057T priority patent/SMT201800057T1/it
Priority to RS20180086A priority patent/RS56901B1/sr
Priority to PL12797167T priority patent/PL2718293T3/pl
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of EP2718293A1 publication Critical patent/EP2718293A1/fr
Publication of EP2718293A4 publication Critical patent/EP2718293A4/fr
Publication of EP2718293B1 publication Critical patent/EP2718293B1/fr
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to novel pyridopyrazine compounds
  • Spleen Tyrosine Kinase is a member of the Syk family of tyrosine kinases, and is a regulator of early B-cell development as well as mature B-cell activation, signaling, and survival.
  • Syk is a non-receptor tyrosine kinase that plays critical roles in
  • immunoreceptor- and integrin-mediated signaling in a variety of cell types, including B cells, macrophages, monocytes, mast cells, eosinophils, basophils, neutrophils, dendritic cells, T cells, natural killer cells, platelets, and osteoclasts.
  • Immunoreceptors as described herein include classical immunoreceptors and immunoreceptor-like molecules.
  • Classical immunoreceptors include B-cell and T-cell antigen receptors as well as various immunoglobulin receptors (Fc receptors).
  • Immunoreceptor-like molecules are either structurally related to immunoreceptors or participate in similar signal transduction pathways, and are primarily involved in non- adaptive immune functions, including, for example, neutrophil activation, natural killer cell recognition, and osteoclast activity. Integrins are cell surface receptors that play key roles in the control of leukocyte adhesion and activation in both innate and adaptive immunity.
  • Syk is essential for B-cell activation through B-cell receptor (BCR) signaling.
  • BCR B-cell receptor
  • SYK becomes activated upon binding to phosphorylated BCR and thus initiates the early signaling events following BCR activation.
  • B-cell signaling through BCR can lead to a wide range of biological outputs, which in turn depend on the developmental stage of the B-cell.
  • the magnitude and duration of BCR signals must be precisely regulated.
  • Aberrant BCR-mediated signaling can cause disregulated B- cell activation and/or the formation of pathogenic auto-antibodies leading to multiple autoimmune and/or inflammatory diseases.
  • Mice lacking Syk show impaired maturation of B-cells, diminished immunoglobulin production, compromised T-cell- independent immune responses, and marked attenuation of the sustained calcium sign upon BCR stimulation.
  • a large body of evidence supports the role of B-cells and the humoral immune system in the pathogenesis of autoimmune and/or inflammatory diseases.
  • Protein- based therapeutics such as Rituxan developed to deplete B-cells represent an approach to the treatment of a number of autoimmune and inflammatory diseases.
  • Auto-antibodies and their resulting immune complexes are known to play pathogenic roles in autoimmune disease and/or inflammatory disease.
  • the pathogenic response to these antibodies is dependent on signaling through Fc Receptors, which is, in turn, dependent upon Syk. Because of Syk's role in B-cell activation, as well as FcR dependent signaling, inhibitors of Syk can be useful as inhibitors of B-cell mediated pathogenic activity, including autoantibody production. Therefore, inhibition of Syk enzymatic activity in cells is proposed as a treatment for autoimmune disease through its effects on autoantibody production.
  • Syk also plays a key role in FCERI mediated mast cell degranulation and eosinophil activation.
  • Syk binds to the phosphorylated gamma chain of FCERI via its SH2 domains and is essential for downstream signaling.
  • Syk deficient mast cells demonstrate defective degranulation, and arachidonic acid and cytokine secretion. This also has been shown for pharmacologic agents that inhibit Syk activity in mast cells.
  • Syk antisense oligonucleotides inhibit antigen-induced infiltration of eosinophils and neutrophils in an animal model of asthma.
  • Syk deficient eosinophils also show impaired activation in response to FCERI stimulation. Therefore, small molecule inhibitors of Syk may be useful for treatment of allergy-induced inflammatory diseases including asthma.
  • Syk is also expressed in mast cells and monocytes and has been shown to be important for the function of these cells. For example, Syk deficiency in mice is associated with impaired IgE-mediated mast cell activation, which causes marked diminution of TNF-alpha and other inflammatory cytokine release. Additionally, Syk inhibitors have been shown to inhibit antigen-induced passive cutaneous anaphylaxsis, bronchoconstriction and bronchial edema in rats.
  • the inhibition of Syk activity can be useful for the treatment of allergic disorders, autoimmune diseases, and inflammatory diseases, such as: SLE, rheumatoid arthritis, multiple vasculitides, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDs) and asthma.
  • SLE rheumatoid arthritis
  • multiple vasculitides idiopathic thrombocytopenic purpura
  • IPP idiopathic thrombocytopenic purpura
  • COPD chronic obstructive pulmonary disease
  • ARDs adult respiratory distress syndrome
  • Syk has been reported to play an important role in ligand-independent tonic signaling through the B-cell receptor, known to be an important survival signal in B-cells.
  • inhibition of Syk activity may be useful in treating certain types of cancer, including B-cell lymphoma and leukemia.
  • R 1 is independently chosen from hydrogen, halo, -CN, hydroxyl, optionally substituted C1 -C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted amino, and optionally substituted Ci-C6 alkoxy,
  • R 2 is -NR 5 R 6 , -OR 7 , -S(O) n R 8 , -C(O)R 9 , -C(O)OR 7 , -C(O)NR 5 R 6 , -NR 5 C(O)R 9 , -NR 5 S(O) n R 8 , -NR 5 S(O) n NR 10 R 11 , -NR 5 C(O)OR 7 , -NR 5 C(O)NR 10 R 11 , -S(O) n NR 5 R 6 , optionally substituted lower alkyl, optionally substituted alkenyl, and optionally substituted alkynyl;
  • R 3 and R 4 are independently selected from hydrogen, alkyl, cycloalkyi, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, -NR 5 R 6 , -OR 7 , -S(O) n R 8 , - C(O)R 9 , -C(O)OR 7 , -CN, -C(O)NR 5 R 6 , -NR 5 C(O)R 9 , -NR 5 S(O) n R 8 , -NR 5 S(O) n NR 10 R 11 , -NR 5 C(O)OR 7 , -NR 5 C(O)NR 10 R 11 , -NO 2 , -S(O) n NR 5 R 6 , optionally substituted lower alkyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted heteroaryl, optionally substituted aryl, optionally
  • R 3 and R 4 together with the N atom to which they are attached, can form a 4-12 membered mono-cyclic, fused bicyclic or spirocyclic ring optionally containing an additional 1 -3 hetero-atoms chosen from N, O and S, which is optionally
  • n 0, 1 or 2
  • n 1 or 2
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyi, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally
  • Ci-C 4 alkyi cycloalkyl, aryl, heterocycle, heteroaryl, aryl-Ci-C 4 alkyi-, heteroaryl-C C 4 alkyi-, C C 4 haloalkyi-, -OCi-C 4 alkyi,
  • -OC1-C4 alkylphenyl -C1-C4 alkyl-OH, -C1-C4 alkyl-0-Ci-C 4 alkyi, -OC1-C4 haloalkyi, halo, -OH, -NH 2 , -d-C 4 alkyl-NH 2 , -N(Ci-C 4 alkyl)(C C 4 alkyi), -NH(Ci-C 4 alkyi), -N(Ci-C 4 alkyl)(Ci-C 4 alkylphenyl), -NH(Ci-C 4 alkylphenyl), cyano, nitro, oxo, -CO2H, -C(O)OCi-C 4 alkyi, -CON(Ci-C 4 alkyl)(Ci-C 4 alkyi), -CONH(Ci-C 4 alkyi), -CONH 2 , -NHC(O)(Ci-C
  • -C(O)Ci-C 4 haloalkyi -OC(O)Ci-C 4 alkyi, -SO 2 (C C 4 alkyi), -SO 2 (phenyl), - SO 2 (Ci-C 4 haloalkyi), -SO 2 NH 2 , -SO 2 NH(C r C 4 alkyi), -SO 2 NH(phenyl), - NHSO 2 (Ci-C 4 alkyi), -NHSO 2 (phenyl), and -NHSO 2 (d-C 4 haloalkyi), in which each of phenyl, aryl, heterocycle, and heteroaryl is optionally substituted by one or more groups chosen from halo, cycloalkyl, heterocycle, Ci-C 4 alkyi, Ci-C 4 haloalkyi-, -OC1- C 4 alkyi, C1-C4 alkyl-OH, -C C 4 alkyl-O-C C 4 alkyi
  • composition comprising at least one compound and/or at least one pharmaceutically acceptable salt thereof described herein and at least one pharmaceutically acceptable carrier.
  • Also provided is a method of inhibiting the activity of Syk kinase comprising inhibiting said activity with an effective amount of at least one compound and/or at least one pharmaceutically acceptable salt thereof described herein.
  • Also provided is a method of treating a subject with a recognized inflammatory disease responsive to inhibition of Syk comprising administering to said subject in recognized need thereof an effective amount to treat said disease of at least one compound and/or at least one pharmaceutically acceptable salt thereof described herein.
  • a dash (“-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent.
  • -CONH 2 is attached through the carbon atom.
  • alkyl refers to a straight or branched hydrocarbon, containing 1 -18, preferably 1 -12, more preferably 1 -6 carbon atoms.
  • alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, /-propyl, n-butyl, /- butyl, and /-butyl.
  • “Lower alkyl” refers to a straight or branched hydrocarbon, containing 1 -6, preferably 1 -4 carbon atoms.
  • alkoxy is meant a straight or branched alkyl group containing 1 -18, preferably 1 -12, more preferably 1 -6 carbon atoms attached through an oxygen bridge such as, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec- butoxy, tert-butoxy, pentoxy, 2-pentyloxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, 3-methylpentoxy, and the like.
  • Alkoxy groups will usually have from 1 to 6 carbon atoms attached through the oxygen bridge.
  • Lower alkoxy refers to a straight or branched alkoxy, wherein the alkyl portion contains 1 -6 , preferably 1 -4 carbon atoms.
  • alkenyl groups include, but are not limited to, vinyl, 2-propenyl, and 2- butenyl.
  • alkynyl refers to a straight or branched hydrocarbon, containing one or more C ⁇ C triple bonds and 2-10, preferably 2-6 carbon atoms.
  • alkynyl groups include, but are not limited to, ethynyl, 2-propynyl, and 2- butynyl.
  • cycloalkyl refers to saturated and partially unsaturated cyclic hydrocarbon groups having 3 to 12, preferably 3 to 8 carbon atoms.
  • cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.
  • the ring may be saturated or have one or more double bonds (i.e. partially unsaturated), but not fully conjugated, and not aryl, as defined herein.
  • Aryl encompasses:
  • bicyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, naphthalene, indane, and 1 ,2,3,4-tetrahydroquinoline; and tricyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, fluorene.
  • aryl includes 5- and 6-membered carbocyclic aromatic rings fused to a 5- to 7-membered heterocyclic ring containing one or more heteroatoms selected from N, O, and S, provided that the point of attachment is at the carbocyclic aromatic ring.
  • Bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals.
  • Bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in "-yl” by removal of one hydrogen atom from the carbon atom with the free valence are named by adding "-idene” to the name of the corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene.
  • Aryl does not encompass or overlap in any way with heteroaryl, separately defined below. Hence, if one or more carbocyclic aromatic rings are fused with a heterocyclic aromatic ring, the resulting ring system is heteroaryl, not aryl, as defined herein.
  • halo includes fluoro, chloro, bromo, and iodo, and the term
  • halogen includes fluorine, chlorine, bromine, and iodine.
  • heteroaryl refers to aryl
  • 8- to 12-membered bicyclic rings containing one or more, for example, from 1 to 4, or, in some embodiments, from 1 to 3, heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one heteroatom is present in an aromatic ring; and
  • heteroaryl includes a 5- to 7-membered heterocyclic aromatic ring fused to a 5- to 7-membered cycloalkyl ring.
  • bicyclic heteroaryl ring systems wherein only one of the rings contains one or more heteroatoms, the point of attachment is at the heteroaromatic ring.
  • the total number of S and O atoms in the heteroaryl group exceeds 1 , those heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In some embodiments, the total number of S and O atoms in the aromatic heterocycle is not more than 1 .
  • heteroaryl groups include, but are not limited to, (as numbered from the linkage position assigned priority 1 ), 2-pyridyl, 3-pyridyl, 4-pyridyl, 2,3- pyrazinyl, 3,4-pyrazinyl, 2,4-pyrimidinyl, 3,5-pyrimidinyl, 1 -pyrazolyl, 2,3-pyrazolyl, 2,4-imidazolinyl, isoxazolyl, oxazolyl, thiazolyl, thiadiazolyl, tetrazolyl, thienyl, benzothienyl, furyl, benzofuryl, benzoimidazolinyl, indolinyl, pyridizinyl, triazolyl, quinolinyl, pyrazolyl, and 5,6,7,8-tetrahydroisoquinoline.
  • Bivalent radicals derived from univalent heteroaryl radicals whose names end in "-yl” by removal of one hydrogen atom from the atom with the free valence are named by adding "-idene" to the name of the corresponding univalent radical, e.g., a pyridyl group with two points of attachment is a pyridylidene.
  • Heteroaryl does not encompass or overlap with aryl as defined above.
  • Substituted heteroaryl also includes ring systems substituted with one or more oxide (-O " ) substituents, such as pyridinyl N-oxides.
  • heterocycle is meant a 4- to 12-membered monocyclic, bicyclic or tricyclic saturated or partially unsaturated ring containing at least 2 carbon atoms in addition to 1 -3 heteroatoms independently selected from oxygen, sulfur, and nitrogen.
  • Heterocycle also refers to 5- to 7-membered heterocyclic ring containing one or more heteroatoms selected from N, O, and S fused with 5-, 6-, and/or 7-membered cycloalkyl, heterocyclic, carbocyclic aromatic or heteroaromatic ring, provided that the point of attachment is at the heterocyclic ring.
  • Heterocycle also refers to an aliphatic spirocyclic ring containing one or more heteroatoms selected from N, O, and S, provided that the point of attachment is at the heterocyclic ring.
  • the rings may be saturated or have one or more double bonds (i.e. partially unsaturated).
  • the heterocycle can be substituted by oxo.
  • the point of the attachment may be carbon or heteroatom in the heterocyclic ring.
  • a heterocyle is not a heteroaryl as defined herein.
  • Suitable heterocycles include, for example (as numbered from the linkage position assigned priority 1 ), 1 -pyrrol id inyl, 2-pyrrolidinyl, 2,4-imidazolidinyl, 2,3- pyrazolidinyl, 1 -piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, and 2,5- piperazinyl.
  • Morpholinyl groups are also contemplated, including 2-morpholinyl and 3-morpholinyl (numbered wherein the oxygen is assigned priority 1 ).
  • Substituted heterocycle also includes ring systems substituted with one or more oxo moieties, such as piperidinyl /V-oxide, morpholinyl-/V-oxide, 1 -oxo-1 -thiomorpholinyl and 1 ,1 - dioxo-1 -thiomorpholinyl.
  • oxo moieties such as piperidinyl /V-oxide, morpholinyl-/V-oxide, 1 -oxo-1 -thiomorpholinyl and 1 ,1 - dioxo-1 -thiomorpholinyl.
  • a stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture, and subsequent formulation as an agent having at least practical utility.
  • substituents are named into the core structure. For example, it is to be understood that when
  • (cycloalkyl)alkyl is listed as a possible substituent, the point of attachment of this substituent to the core structure is in the alkyl portion.
  • substituted with one or more groups refers to two hydrogens on the designated atom or group being independently replaced with two selections from the indicated group of substituents.
  • substituted with one or more groups refers to two hydrogens on the designated atom or group being independently replaced with two selections from the indicated group of substituents.
  • substituted with one or more groups refers to three hydrogens on the designated atom or group being independently replaced with three selections from the indicated group of substituents. In some embodiments, “substituted with one or more groups” refers to four hydrogens on the designated atom or group being independently replaced with four selections from the indicated group of substituents.
  • such compounds include Z- and E- forms (or cis- and trans- forms) of compounds with carbon-carbon double bonds.
  • the term "compound” is intended to include, to the extent they can be made without undue experimentation, all tautomeric forms of the compound.
  • Such compounds also include crystal forms including polymorphs and clathrates, to the extent they can be made by one of ordinary skill in the art without undue experimentation.
  • salt is intended to include all isomers, racemates, other mixtures, Z- and E- forms, tautomeric forms and crystal forms of the salt of the compound, to the extent they can be made by one of ordinary skill in the art without undue experimentation.
  • “Pharmaceutically acceptable salts” include, but are not limited to salts with inorganic acids, such as hydrochlorate, phosphate, diphosphate, hydrobromate, sulfate, sulfinate, nitrate, and like salts; as well as salts with an organic acid, such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate,
  • pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium, and ammonium.
  • the free base can be obtained by basifying a solution of the acid salt.
  • an addition salt particularly a
  • pharmaceutically acceptable addition salt may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in
  • a "solvate,” such as a “hydrate,” is formed by the interaction of a solvent and a compound.
  • the term “compound” is intended to include solvates, including hydrates, of compounds, to the extent they can be made by one of ordinary skill in the art by routine experimentation.
  • “salts” includes solvates, such as hydrates, of salts, to the extent they can be made by one of ordinary skill in the art by routine experimentation.
  • Suitable solvates are pharmaceutically acceptable solvates, such as hydrates, including monohydrates and hemi-hydrates, to the extent they can be made by one of ordinary skill in the art by routine experimentation.
  • a "chelate” is formed by the coordination of a compound to a metal ion at two (or more) points.
  • the term “compound” is intended to include chelates of
  • salts includes chelates of salts.
  • a "non-covalent complex” is formed by the interaction of a compound and another molecule wherein a covalent bond is not formed between the compound and the molecule.
  • complexation can occur through van der Waals interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding).
  • Such non-covalent complexes are included in the term "compound” to the extent they can be made by one of ordinary skill in the art by routine experimentation.
  • hydrogen bond refers to a form of association between an electronegative atom (also known as a hydrogen bond acceptor) and a hydrogen atom attached to a second, relatively electronegative atom (also known as a hydrogen bond donor).
  • electronegative atom also known as a hydrogen bond acceptor
  • hydrogen bond donor and acceptors are well understood in medicinal chemistry (G. C. Pimentel and A. L. McClellan, The
  • active agent is used to indicate a chemical substance which has biological activity.
  • an “active agent” is a chemical substance having pharmaceutical utility.
  • Treating,” “treat,” or “treatment” or “alleviation” refers to administering at least one compound and/or at least one pharmaceutically acceptable salt thereof described herein to a subject that has a disease or disorder, or has a symptom of a disease or disorder, or has a predisposition toward a disease or disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect cancer, the symptoms of the disease or disorder, or the predisposition toward the disease or disorder.
  • the disease or disorder may be cancer.
  • the disease or disorder may be an inflammatory disease.
  • the term "effective amount” refers to an amount of at least one compound and/or at least one pharmaceutically acceptable salt thereof described herein effective to "treat", as defined above, a disease or disorder in a subject responsive to the inhibition of Syk.
  • the effective amount may cause any of the changes observable or measurable in a subject as described in the definition of "treating,” "treat,”
  • the effective amount can reduce the number of cancer or tumor cells; reduce the tumor size; inhibit or stop tumor cell infiltration into peripheral organs including, for example, the spread of tumor into soft tissue and bone; inhibit and stop tumor metastasis; inhibit and stop tumor growth; relieve to some extent one or more of the symptoms associated with the cancer, reduce morbidity and mortality; improve quality of life; or a combination of such effects.
  • An effective amount may be an amount sufficient to decrease the symptoms of a disease responsive to inhibition of Syk kinase
  • an effective amount may also refer to an amount of at least one compound and/or at least one pharmaceutically acceptable salt described herein effective to inhibit the activity of Syk in a subject responsive to the inhibition of Syk..
  • inhibitors indicates a decrease in the baseline activity of a biological activity or process.
  • Inhibition of Syk refers to a decrease in the activity of Syk kinase as a direct or indirect response to the presence of at least one compound and/or at least one pharmaceutically acceptable salt thereof described herein, relative to the activity of Syk kinase in the absence of the at least one compound and/or the at least one pharmaceutically acceptable salt thereof.
  • the decrease in activity may be due to the direct interaction of the at least one compound and/or at least one pharmaceutically acceptable salt thereof described herein with the Syk kinase, or due to the interaction of the at least one compound and/or at least one pharmaceutically acceptable salt thereof described herein, with one or more other factors that in turn affect the at least one kinase activity.
  • the presence of at least one compound and/or at least one pharmaceutically acceptable salt thereof described herein may decrease the at least one kinase activity by directly binding to the Syk kinase, by causing (directly or indirectly) another factor to decrease the at least one kinase activity, or by (directly or indirectly) decreasing the amount of the at least one kinase present in the cell or organism.
  • R 1 is independently chosen from hydrogen, halo, -CN, hydroxyl, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted amino, and optionally substituted Ci-C 6 alkoxy,
  • R 2 is -NR 5 R 6 , -OR 7 , -S(O) n R 8 , -C(O)R 9 , -C(O)OR 7 , -C(O)NR 5 R 6 , -NR 5 C(O)R 9 , -NR 5 S(O) n R 8 , -NR 5 S(O) n NR 10 R 11 , -NR 5 C(O)OR 7 , -NR 5 C(O)NR 10 R 11 , -S(O) n NR 5 R 6 , optionally substituted lower alkyl, optionally substituted alkenyl, and optionally substituted alkynyl;
  • R 3 and R 4 are independently selected from hydrogen, alkyl, cycloalkyi, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, -NR 5 R 6 , -OR 7 , -S(O) n R 8 , - C(O)R 9 , -C(O)OR 7 , -CN, -C(O)NR 5 R 6 , -NR 5 C(O)R 9 , -NR 5 S(O) n R 8 , -NR 5 S(O) n NR 10 R 11 , -NR 5 C(O)OR 7 , -NR 5 C(O)NR 10 R 11 , -NO 2 , -S(O) n NR 5 R 6 , optionally substituted lower alkyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted heteroaryl, optionally substituted aryl, optionally
  • R 3 and R 4 together with the N atom to which they are attached, can form a 4-12 membered mono-cyclic, fused bicyclic or spirocyclic ring optionally containing an additional 1 -3 hetero-atoms chosen from N, O and S, which is optionally
  • n 0, 1 or 2
  • n 1 or 2
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyi, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally
  • -OC1-C4 alkylphenyl -C1-C4 alkyl-OH, -C1-C4 alkyl-0-Ci-C 4 alkyl, -OC1-C4 haloalkyl, halo, -OH, -NH 2 , -d-C 4 alkyl-NH 2 , -N(Ci-C 4 alkyl)(C C 4 alkyl), -NH(Ci-C 4 alkyl), -N(Ci-C 4 alkyl)(Ci-C 4 alkylphenyl), -NH(Ci-C 4 alkylphenyl), cyano, nitro, oxo, -CO2H, -C(O)OCi-C 4 alkyl, -CON(Ci-C 4 alkyl)(Ci-C 4 alkyl), -CONH(Ci-C 4 alkyl), -CONH 2 , -NHC(O)(Ci-C
  • -C(O)Ci-C 4 haloalkyl -OC(O)Ci-C 4 alkyl, -SO 2 (C C 4 alkyl), -SO 2 (phenyl), - SO 2 (Ci-C 4 haloalkyl), -SO 2 NH 2 , -SO 2 NH(C r C 4 alkyl), -SO 2 NH(phenyl), - NHSO 2 (Ci-C 4 alkyl), -NHSO 2 (phenyl), and -NHSO 2 (d-C 4 haloalkyl), in which each of phenyl, aryl, heterocycle, and heteroaryl is optionally substituted by one or more groups chosen from halo, cycloalkyl, heterocycle, Ci-C 4 alkyl, Ci-C 4 haloalkyl-, -OC1- C 4 alkyl, C1-C4 alkyl-OH, -C C 4 alkyl-O-C C 4 alkyl
  • R 1 is independently chosen from hydrogen, halo, hydroxyl, -CN, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted amino, and optionally substituted Ci-C6 alkoxy.
  • R 1 is independently chosen from hydrogen, halo, -CN, hydroxyl; or is chosen from methyl, ethyl, n-propyl, /-propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, /V-methylamino, /V-ethylamino, N-n- propylamino, /V-/-propylamino, methoxy, ethoxy, propoxy, isopropoxy, each of which is optionally substituted.
  • R 1 is independently chosen from hydrogen, hydroxyl, and alkyl.
  • R 2 is C 5 -Cioaryl, 3-8 membered heterocycle, or 5-10 membered heteroaryl, which is optionally substituted by one or more groups selected from halo, -NR 5 R 6 , -OR 7 , -S(O) n R 8 , -C(O)R 9 , -C(O)OR 7 , -CN, -C(O)NR 5 R 6 , - NR 5 C(O)R 9 , -NR 5 S(O) n R 8 , -NR 5 S(O) n NR 10 R 1 1 , -NR 5 C(O)OR 7 , -NR 5 C(O)NR 10 R 1 1 , - NO 2 , -S(O) n NR 5 R 6 , optionally substituted Ci-C 6 alkyl, optionally substituted C 3 -C 8 cycloalky
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyi, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower
  • alkylsulfonyl optionally substituted lower alkylacyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide.
  • R 2 is independently chosen from phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, quinolinyl, pyrrolidinyl, tetrahydrofuryl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, diazepanyl, oxazepanyl, which is optionally substituted by one or more groups selected from halo, -NR 5 R 6 , -OR 7 , -S(O) n R 8 , -C(O)R 9 , -C
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyi, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally
  • R 2 is chosen from
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyi, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally
  • R 2 is chosen from
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyi, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally
  • R 2 is
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyi, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally
  • R 2 is which is optionally substituted by one or more groups selected from halo, - NR 5 R 6 , -OR 7 , -S(O) n R 8 , -C(O)R 9 , -C(O)OR 7 , -CN, -C(O)NR 5 R 6 , -NR 5 C(O)R 9 , - NR 5 S(O) n R 8 , -NR 5 S(O) n NR 10 R 11 , -NR 5 C(O)OR 7 , -NR 5 C(O)NR 10 R 11 , -NO 2 , - S(O) n NR 5 R 6 ; or selected from methyl, ethyl, n-propyl, /-propyl, n-butyl, /-butyl, and t- butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopen
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 1 1 are independently selected from hydrogen, alkyl, cycloalkyi, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally
  • R 3 and R 4 are independently selected from hydrogen, Ci-C 6 alkyl, C 3 -C 8 cycloalkyi, C5-C10 aryl, 5-10 membered heteroaryl, and 3-8 membered heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, -NR 5 R 6 , -OR 7 , -S(O) n R 8 , -C(O)R 9 , - C(O)OR 7 , -CN, -C(O)NR 5 R 6 , -NR 5 C(O)R 9 , -NR 5 S(O) n R 8 , -NR 5 S(O) n NR 10 R 1 1 , - NR 5 C(O)OR 7 , -NR 5 C(O)NR 10 R 1 1 , -NO 2 , -S(O) n NR 5 R 6 , optionally substituted d-C 6
  • R 3 and R 4 together with the N atom to which they are attached, can form a 4-12 membered mono-cyclic, fused bicyclic or spirocyclic ring optionally containing an additional 1 -3 hetero-atoms chosen from N, O and S, which is optionally
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyi, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally
  • R 3 and R 4 are independently selected from hydrogen, methyl, ethyl, n-propyl, /-propyl, n-butyl, /-butyl, and f-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, quinolinyl, and pyrrolidinyl, tetrahydrofuryl, piperidinyl, piperaz
  • R 3 and R 4 together with the N atom to which they are attached, can form a 4-12 membered mono-cyclic, fused bicyclic or spirocyclic ring optionally containing an additional 1 -3 hetero-atoms chosen from N, O and S, which is optionally
  • quinolinyl optionally substituted phenyl, naphthyl, optionally substituted C2-C6 alkenyl, and optionally substituted C2-C6 alkynyl, each of which is optional
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyi, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally
  • R 4 is H and R 3 is lower alkyi, which is optionally substituted with one or more groups selected from alkyi, cycloalkyi, heterocycle and heteroaryl, each of which is optionally substituted by one or more groups chosen from halo, -NR 5 R 6 , -OR 7 , -S(O)nR 8 , -C(O)R 9 , -C(O)OR 7 , -CN, -C(O)NR 5 R 6 , - NR 5 C(O)R 9 , -NR 5 S(O) n R 8 , -NR 5 S(O) n NR 10 R 1 1 , -NR 5 C(O)OR 7 , -NR 5 C(O)NR 10 R 1 1 , - NO2, -S(O) n NR 5 R 6 , optionally substituted lower alkyi, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyi, cycloalkyi, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyi, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally
  • R 3 and R 4 together with the N atom to which they are attached can form a 4-12 membered mono-cyclic ring optionally containing an additional 1 -3 hetero-atoms chosen from N, O and N, which is optionally substituted with one or more groups selected from halo, -NR 5 R 6 , -OR 7 , -S(O) n R 8 , -C(O)R 9 , - C(O)OR 7 , -CN, -C(O)NR 5 R 6 , -NR 5 C(O)R 9 , -NR 5 S(O)nR 8 , -NR 5 S(O)nNR 10 R 11 , - NR 5 C(O)OR 7 , -NR 5 C(O)NR 10 R 1 1 , -NO 2 , -S(O)nNR 5 R 6 , optionally substituted lower alkyi, optionally substituted cycloalkyi, optionally substituted heterocycle
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyi, cycloalkyi, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally
  • R 3 and R 4 together with the N atom to which they are attached can form a 7-14 membered fused bicyclic ring optionally containing an additional 1 -3 hetero-atoms chosen from N, O and N, which is optionally substituted with one or more groups selected from halo, -NR 5 R 6 , -OR 7 , -S(O)nR 8 , -C(O)R 9 , - C(O)OR 7 , -CN, -C(O)NR 5 R 6 , -NR 5 C(O)R 9 , -NR 5 S(O)nR 8 , -NR 5 S(O)nNR 10 R 11 , - NR 5 C(O)OR 7 , -NR 5 C(O)NR 10 R 1 1 , -NO 2 , -S(O)nNR 5 R 6 , optionally substituted lower alkyl, optionally substituted cycloalkyi, optionally substituted hetero
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyi, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally
  • R 3 and R 4 together with the N atom to which they are attached can form a 7-14 membered spirocyclic ring optionally containing an additional 1 -3 hetero-atoms chosen from N, O and N, which is optionally substituted with one or more groups selected from halo, -NR 5 R 6 , -OR 7 , -S(O)nR 8 , -C(O)R 9 , - C(O)OR 7 , -CN, -C(O)NR 5 R 6 , -NR 5 C(O)R 9 , -NR 5 S(O)nR 8 , -NR 5 S(O)nNR 10 R 11 , - NR 5 C(O)OR 7 , -NR 5 C(O)NR 10 R 1 1 , -NO 2 , -S(O)nNR 5 R 6 , optionally substituted lower alkyl, optionally substituted cycloalkyi, optionally substituted hetero
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyi, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyi, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally
  • the optionally substituted lower alkyl is chosen from CF 3 , CF 2 H, aminoalkyl, hydroxyalkyl, alkoxyalkyl, and haloalkyl.
  • compounds of formula (1 ) can react with compounds of formula (2), wherein n, R 1 , R 2 and R 3 are as defined herein, X 1 and X 2 are halo chosen from CI, Br or I, in the presence of a base, such as but not limited to K2CO3, Na 2 CO 3 , NaH, Et 3 N or diisopropylethylamine (DIPEA), to give compounds of formula (3) that can react with compounds of formula (4), wherein R 2 is as defined herein, M is chosen from boronic acid/ester or a tin substituted with Ci-C 4 alkyl groups, under the catalysis of a palladium reagent, such as but not limited to PdC ⁇ , Pd(OAc) 2 Pd 2 (dba) 3 or Pd(PPh 3 ) 4 , and a ligand, such as but not limited to Ph 3 P, f Bu 3 P, 2,2'- bis(diphenylphos
  • the compounds thus obtained can be further modified at their peripheral positions to provide the desired compounds.
  • Synthetic chemistry transformations are described, for example, in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3 rd Ed., John Wiley and Sons (1999); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) and subsequent editions thereof.
  • the at least one compound and/or at least one pharmaceutically acceptable salt described herein can be purified by column chromatography, high performance liquid chromatography, crystallization, or other suitable methods.
  • a composition comprising at least one compound and/or at least one pharmaceutically acceptable salt described herein, and at least one pharmaceutically acceptable carrier.
  • a composition comprising at least one compound and/or at least one pharmaceutically acceptable salt described herein, can be administered in various known manners, such as orally, parenterally, by inhalation spray, or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous,
  • An oral composition can be any orally acceptable dosage form including, but not limited to, tablets, capsules, emulsions, and aqueous suspensions, dispersions and solutions.
  • Commonly used carriers for tablets include lactose and corn starch.
  • Lubricating agents, such as magnesium stearate, are also typically added to tablets.
  • useful diluents include lactose and dried corn starch.
  • the active ingredient can be suspended or dissolved in an oily phase combined with emulsifying or suspending agents. If desired, certain sweetening, flavoring, or coloring agents can be added.
  • a sterile injectable composition e.g., aqueous or oleaginous suspension
  • a sterile injectable composition can be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents.
  • the sterile injectable Intermediate can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1 ,3-butanediol.
  • suitable dispersing or wetting agents such as, for example, Tween 80
  • the sterile injectable Intermediate can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1 ,3-butanediol.
  • the pharmaceutically acceptable vehicles and solvents that can be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium (e.g., synthetic mono- or di-glycerides).
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the Intermediate of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions can also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents.
  • An inhalation composition can be prepared according to techniques well known in the art of pharmaceutical formulation and can be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
  • a topical composition can be formulated in form of oil, cream, lotion, ointment, and the like.
  • suitable carriers for the composition include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohols (greater than C12).
  • the pharmaceutically acceptable carrier is one in which the active ingredient is soluble.
  • Emulsifiers, stabilizers, humectants and antioxidants may also be included as well as agents imparting color or fragrance, if desired.
  • transdermal penetration enhancers may be employed in those topical formulations. Examples of such enhancers can be found in U.S. Patents 3,989,816 and 4,444,762.
  • Creams may be formulated from a mixture of mineral oil, self-emulsifying beeswax and water in which mixture the active ingredient, dissolved in a small amount of an oil, such as almond oil, is admixed.
  • An example of such a cream is one which includes about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil and about 1 part almond oil.
  • Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil, such as almond oil, with warm soft paraffin and allowing the mixture to cool.
  • An example of such an ointment is one which includes about 30% by weight almond oil and about 70% by weight white soft paraffin.
  • a pharmaceutically acceptable carrier refers to a carrier that is compatible with active ingredients of the composition (and in some embodiments, capable of stabilizing the active ingredients) and not deleterious to the subject to be treated.
  • solubilizing agents such as cyclodextrins (which form specific, more soluble complexes with the at least one compound and/or at least one
  • compositions for delivery of the active ingredients include colloidal silicon dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and pigments such as D&C Yellow # 10.
  • Suitable in vitro assays can be used to preliminarily evaluate the efficacy of the at least one compound and/or at least one pharmaceutically acceptable salt described herein, in inhibiting the activity of Syk kinase.
  • the at least one compound and/or at least one pharmaceutically acceptable salt described herein can further be examined for efficacy in treating inflammatory disease by in vivo assays.
  • the compounds described herein, and/or the pharmaceutically acceptable salts thereof can be administered to an animal (e.g., a mouse model) having inflammatory disease and its therapeutic effects can be accessed. Based on the results, an appropriate dosage range and administration route for animals, such as humans, can also be determined.
  • the method comprises contacting the at least one kinase with an amount of at least one compound and/or at least one pharmaceutically acceptable salt described herein effective to inhibit the activity of the Syk kinase.
  • the at least one compound and/or at least one pharmaceutically acceptable salt described herein can be used to achieve a beneficial therapeutic or prophylactic effect, for example, in subjects with an inflammatory disease or inflammatory disorder.
  • inflammatory disease or "inflammatory disorder” refers to pathological states resulting in inflammation, typically caused by neutrophil chemotaxis. Examples of such disorders include inflammatory skin diseases including psoriasis and atopic dermatitis; systemic scleroderma and sclerosis;
  • IBD inflammatory bowel disease
  • ischemic reperfusion disorders including surgical tissue reperfusion injury, myocardial ischemic conditions such as myocardial infarction, cardiac arrest, reperfusion after cardiac surgery and constriction after percutaneous transluminal coronary angioplasty, stroke, and abdominal aortic aneurysms; cerebral edema secondary to stroke; cranial trauma, hypovolemic shock; asphyxia; adult respiratory distress syndrome; acute-lung injury; Behcet's Disease; dermatomyositis; polymyositis; multiple sclerosis (MS); dermatitis; meningitis;
  • IBD inflammatory bowel disease
  • myocardial ischemic conditions such as myocardial infarction, cardiac arrest, reperfusion after cardiac surgery and constriction after percutaneous transluminal coronary angioplasty, stroke, and abdominal aortic aneurysms
  • cerebral edema secondary to stroke cranial trauma, hypovolemic shock; asphyxia; adult respiratory distress
  • encephalitis uveitis; osteoarthritis; lupus nephritis; autoimmune diseases such as rheumatoid arthritis (RA), Sjorgen's syndrome, vasculitis; diseases involving leukocyte diapedesis; central nervous system (CNS) inflammatory disorder, multiple organ injury syndrome secondary to septicaemia or trauma; alcoholic hepatitis;
  • RA rheumatoid arthritis
  • CNS central nervous system
  • bacterial pneumonia bacterial pneumonia
  • antigen-antibody complex mediated diseases including glomerulonephritis; sepsis; sarcoidosis; immunopathologic responses to tissue/organ transplantation; inflammations of the lung, including pleurisy, alveolitis, vasculitis, pneumonia, chronic bronchitis, bronchiectasis, diffuse panbronchiolitis,
  • the preferred indications include, without limitation, chronic inflammation, autoimmune diabetes, rheumatoid arthritis (RA), rheumatoid spondylitis, gouty arthritis and other arthritic conditions, multiple sclerosis (MS), asthma, systhemic lupus erythrematosus, adult respiratory distress syndrome, Behcet's disease, psoriasis, chronic pulmonary inflammatory disease, graft versus host reaction, Crohn's Disease, ulcerative colitis, inflammatory bowel disease (IBD), Alzheimer's disease, and pyresis, along with any disease or disorder that relates to inflammation and related disorders.
  • the at least one compound and/or at least one pharmaceutically acceptable salt described herein can be used to achieve a beneficial therapeutic or prophylactic effect, for example, in subjects with an autoimmune disease.
  • autoimmune disease refers to a disease or disorder arising from and/or directed against an individual's own tissues or organs, or a co-segregate or manifestation thereof, or resulting condition therefrom. Examples of autoimmune diseases include, but are not limited to, lupus, myasthenia gravis, multiple sclerosis (MS), rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease, asthma and idiopathic
  • myeloid proliferative disorder such as myelofibrosis, PV / ET (Post-Polycythemia / Essential Thrombocythemia Myelofibrosis).
  • the at least one compound and/or at least one pharmaceutically acceptable salt described herein is administered in conjunction with another therapeutic agent.
  • the other therapeutic agent is one that is normally administered to patients with the disease or condition being treated.
  • the other therapeutic agent may be an anti-inflammatory agent or an anti-neoplastic agent, depending on the disease or condition being treated.
  • the at least one compound and/or at least one pharmaceutically acceptable salt described herein may be administered with the other therapeutic agent in a single dosage form or as a separate dosage form.
  • the other therapeutic agent may be administered prior to, at the same time as, or following administration of the at least one compound and/or at least one pharmaceutically acceptable salt described herein.
  • the at least one compound and/or at least one pharmaceutically acceptable salt described herein is administered in conjunction with an anti-inflammatory agent.
  • anti-inflammatory agents include corticosteroids (e.g., fluticasone propionate, beclomethasone dipropionate, mometasone furoate, triamcinolone acetonide or budesonide), disease-modifying agents (e.g., antimalarials, methotrexate, sulfasalazine, mesalamine, azathioprine, 6- mercaptopurine, metronidazole, injectable and oral gold, or D-penicillamine), nonsteroidal antiinflammatory drugs (e.g., acetominophen, aspirin, sodium salicylate, sodium cromoglycate, magnesium salicylate, choline magnesium salicylate, salicylsalicylic acid, ibuprofen, naproxen, diclofenac, diflunis
  • corticosteroids e.g
  • 2,6-dichloropyridine-4-ylamine (10.0 g, 61 mmol) was slowly added in concentrated sulfuric acid (64 mL) at the rate to keep the internal reaction temperature ⁇ 10 °C.
  • the mixture was then cooled to -5 °C and nitric acid (90%, 30 mL) was added dropwise to keep the reaction temperature below 0 °C over a period of 40 minutes.
  • the reaction mixture was stirred at 0 °C for 2 hours and then poured into ice-water (500 mL). The title compound was isolated by filtration and dried in vacuo for the next step.
  • reaction mixture was stirred at room temperature for 1 .5 hours, then diluted with diethyl ether, washed with saturated sodium bicarbonate solution and brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo.
  • the crude residue was dissolved in NMP.
  • Sodium azide (3.00 g, 46.2 mmol) was added, and the resulting suspension was stirred at 80 °C overnight.
  • the reaction mixture was diluted with EtOAc/hexane, washed with brine, then dried over anhydrous sodium sulfate, filtered, and
  • Tetrabutylammonium bromide (1 .06 g, 3.3 mmol) is added to a solution of 1 -(4- bromophenyl)piperidin-4-ol (2.56 g, 10 mmol) in toluene (30 mL). The reaction mixture was cooled to 0 °C and aq. 35% sodium hydroxide (30 mL) was added followed by a drop-wise addition of terf-butyl bromoacetate (2.92 g, 15 mmol). The mixture was then allowed to reach room temperature and was stirred for 17 hours at this temperature.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Conductive Materials (AREA)

Abstract

La présente invention concerne des composés de pyridopyrazine de formule (I), des compositions pharmaceutiques de ceux-ci et des procédés d'utilisation pour ceux-ci, dans lesquels R1, R2, R3, R4 et m sont tels que définis dans la spécification.
EP12797167.9A 2011-06-08 2012-06-07 Pyridopyrazines substituées en tant que nouveaux inhibiteurs de syk Active EP2718293B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SI201231176T SI2718293T1 (en) 2011-06-08 2012-06-07 SUBSTITUTED PYRIDOPIRAZINS AS NEW INHIBITORS OF VRANIC TYROSIN KINASE (SYK)
SM20180057T SMT201800057T1 (it) 2011-06-08 2012-06-07 Piridopirazlne sostituite come nuovi inibitori di syk
RS20180086A RS56901B1 (sr) 2011-06-08 2012-06-07 Supstituisani piridopirazini kao novi syk inhibitori
PL12797167T PL2718293T3 (pl) 2011-06-08 2012-06-07 Podstawione pirydopirazyny jako nowe inhibitory syk
HRP20180139TT HRP20180139T1 (hr) 2011-06-08 2012-06-07 Supstituirani piridopirazini kao novi syk-inhibitori

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2011/075431 WO2012167423A1 (fr) 2011-06-08 2011-06-08 Pyridopyrazines substituées en tant que nouveaux inhibiteurs de syk
PCT/CN2012/076576 WO2012167733A1 (fr) 2011-06-08 2012-06-07 Pyridopyrazines substituées en tant que nouveaux inhibiteurs de syk

Publications (3)

Publication Number Publication Date
EP2718293A1 true EP2718293A1 (fr) 2014-04-16
EP2718293A4 EP2718293A4 (fr) 2014-12-03
EP2718293B1 EP2718293B1 (fr) 2017-10-25

Family

ID=47295336

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12797167.9A Active EP2718293B1 (fr) 2011-06-08 2012-06-07 Pyridopyrazines substituées en tant que nouveaux inhibiteurs de syk

Country Status (32)

Country Link
US (2) US9434726B2 (fr)
EP (1) EP2718293B1 (fr)
JP (2) JP5940148B2 (fr)
KR (1) KR101571720B1 (fr)
CN (1) CN103596952B (fr)
AU (1) AU2012266941B2 (fr)
BR (1) BR112013031405B1 (fr)
CA (1) CA2836227C (fr)
CL (1) CL2013003512A1 (fr)
CY (1) CY1119953T1 (fr)
DK (1) DK2718293T3 (fr)
ES (1) ES2657549T3 (fr)
HR (1) HRP20180139T1 (fr)
HU (1) HUE037934T2 (fr)
IL (1) IL229410A (fr)
LT (1) LT2718293T (fr)
MX (1) MX355671B (fr)
MY (1) MY186599A (fr)
NO (1) NO2718293T3 (fr)
PE (1) PE20141167A1 (fr)
PH (1) PH12013502434A1 (fr)
PL (1) PL2718293T3 (fr)
PT (1) PT2718293T (fr)
RS (1) RS56901B1 (fr)
RU (1) RU2569635C9 (fr)
SG (1) SG195035A1 (fr)
SI (1) SI2718293T1 (fr)
SM (1) SMT201800057T1 (fr)
TW (1) TWI494311B (fr)
UA (1) UA111744C2 (fr)
WO (2) WO2012167423A1 (fr)
ZA (1) ZA201308947B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507458A (ja) * 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
WO2012167423A1 (fr) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Pyridopyrazines substituées en tant que nouveaux inhibiteurs de syk
WO2014028479A1 (fr) 2012-08-13 2014-02-20 Envoy Therapeutics, Inc. Dérivés de quinoxaline en tant que modulateurs du gpr6
WO2014086032A1 (fr) * 2012-12-07 2014-06-12 Hutchison Medipharma Limited Pyridopyrazines substituées utilisées en tant qu'inhibiteurs de syk
US10179783B2 (en) 2014-02-14 2019-01-15 Taketa Pharmaceutical Company Limited Tetrahydropyridopyrazines as modulators of GPR6
KR102431017B1 (ko) 2014-03-19 2022-08-11 베링거 인겔하임 인터내셔날 게엠베하 헤테로아릴 syk 억제제
AU2016280255A1 (en) 2015-06-18 2018-02-08 Cephalon, Inc. 1, 4-substituted piperidine derivatives
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
CN105153211B (zh) * 2015-09-22 2017-02-01 上海晋鲁医药科技有限公司 一种合成1‑(N‑Boc‑4‑哌啶)‑4‑吡唑硼酸频哪醇酯的方法
CN110072865B (zh) 2017-02-08 2022-02-11 中国医药研究开发中心有限公司 吡咯并芳杂环类化合物及其制备方法和医药用途
AU2018302026B2 (en) * 2017-07-18 2022-04-07 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
CN109422741A (zh) * 2017-08-22 2019-03-05 和记黄埔医药（上海）有限公司 化合物的盐及其晶型
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
KR20230043955A (ko) * 2020-07-23 2023-03-31 시토신랩 테라퓨틱스 코., 엘티디. 키나아제 억제 활성을 갖는 화합물
TW202313608A (zh) * 2021-06-04 2023-04-01 美商建南德克公司 ２，８—二氮雜螺［４．５］癸烷化合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022779A (en) * 1974-07-25 1977-05-10 E. R. Squibb & Sons, Inc. Amino derivatives of pyrido(3,4-b)pyrazine carboxylic acids and esters
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP4903997B2 (ja) * 2002-07-02 2012-03-28 サザン リサーチ インスティチュート ＦｔｓＺの阻害剤およびそれらの用途
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
RU2515944C9 (ru) * 2005-11-11 2014-07-20 Этерна Центарис ГмбХ ПРОИЗВОДНЫЕ ПИРИДОПИРАЗИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ФИЗИОЛОГИЧЕСКИХ И/ИЛИ ПАТОФИЗИОЛОГИЧЕСКИХ СОСТОЯНИЙ ПОСРЕДСТВОМ ИНГИБИРОВАНИЯ ФЕРМЕНТОВ ERK, ERK1, ERK2, PI3K, PI3Kальфа, PI3Kбета, PI3Kгамма, PI3Kдельта, PI3K-С2альфа, PI3K-С2бета, PI3K-Vps34р (ВАРИАНТЫ)
TW200938542A (en) * 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
WO2010015520A1 (fr) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Naphtyridines substituées et leur utilisation en tant que médicaments
US8722692B2 (en) * 2009-07-30 2014-05-13 Jianwei Che Compounds and compositions as Syk kinase inhibitors
PT2477987T (pt) * 2009-09-14 2018-03-13 Gilead Sciences Inc Moduladores de recetores do tipo toll
KR20120125267A (ko) 2010-01-29 2012-11-14 베링거 인겔하임 인터내셔날 게엠베하 치환된 나프티리딘 및 ｓｙｋ 키나제 억제제로서의 이의 용도
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
JP2014507458A (ja) * 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
WO2012167423A1 (fr) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Pyridopyrazines substituées en tant que nouveaux inhibiteurs de syk
KR101986484B1 (ko) 2011-07-26 2019-06-10 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴놀린 및 이의 약제로서의 용도

Also Published As

Publication number Publication date
IL229410A (en) 2017-08-31
RU2013158996A (ru) 2015-07-20
US10052330B2 (en) 2018-08-21
HK1190143A1 (zh) 2014-06-27
ES2657549T3 (es) 2018-03-05
NO2718293T3 (fr) 2018-03-24
SI2718293T1 (en) 2018-04-30
UA111744C2 (uk) 2016-06-10
PH12013502434A1 (en) 2014-01-13
HUE037934T2 (hu) 2018-09-28
CA2836227A1 (fr) 2012-12-13
WO2012167733A1 (fr) 2012-12-13
HRP20180139T1 (hr) 2018-05-18
RS56901B1 (sr) 2018-05-31
IL229410A0 (en) 2014-01-30
JP6175484B2 (ja) 2017-08-02
CN103596952B (zh) 2016-05-04
RU2569635C2 (ru) 2015-11-27
JP2016106100A (ja) 2016-06-16
BR112013031405B1 (pt) 2021-12-21
ZA201308947B (en) 2020-02-26
KR20140025559A (ko) 2014-03-04
CY1119953T1 (el) 2018-12-12
SG195035A1 (en) 2013-12-30
PT2718293T (pt) 2018-01-30
US20140121200A1 (en) 2014-05-01
JP5940148B2 (ja) 2016-06-29
AU2012266941A1 (en) 2013-11-28
LT2718293T (lt) 2018-02-12
CN103596952A (zh) 2014-02-19
BR112013031405A2 (pt) 2016-12-06
MX355671B (es) 2018-04-26
TWI494311B (zh) 2015-08-01
EP2718293B1 (fr) 2017-10-25
KR101571720B1 (ko) 2015-11-25
MY186599A (en) 2021-07-29
MX2013014242A (es) 2014-04-14
RU2569635C9 (ru) 2016-07-10
US20160324864A1 (en) 2016-11-10
DK2718293T3 (da) 2018-01-29
EP2718293A4 (fr) 2014-12-03
PE20141167A1 (es) 2014-09-03
CL2013003512A1 (es) 2014-07-18
CA2836227C (fr) 2016-08-16
JP2014516059A (ja) 2014-07-07
WO2012167423A1 (fr) 2012-12-13
US9434726B2 (en) 2016-09-06
TW201305160A (zh) 2013-02-01
NZ617765A (en) 2016-02-26
PL2718293T3 (pl) 2018-05-30
SMT201800057T1 (it) 2018-03-08
AU2012266941B2 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
US10052330B2 (en) Substituted pyrido[3,4-b]pyrazines as Syk inhibitors
KR101541086B1 (ko) 피롤로피리미딘 화합물 및 그 용도
AU2009244291B2 (en) Substituted amides, method of making, and use as Btk inhibitors
HK1223100A1 (zh) 杂环化合物
AU2011306664A1 (en) Pyrazolopyridines as inhibitors of the kinase LRRK2
AU2016320297B2 (en) Pyrazolyl-substituted heteroaryls and their use as medicaments
TW201127385A (en) N-containing heteroaryl derivatives as JAK3 kinase inhibitors
AU2013354552B2 (en) Substituted pyridopyrazines as Syk inhibitors
TW202404952A (zh) Qpctl及qpct之抑制劑
TW202421130A (zh) 作為pi3k抑制劑的異喹啉酮
JP2024534169A (ja) Ｅｇｆｒ阻害剤としての置換アミノピリジン化合物
AU2020403681A1 (en) Compound and composition as pdgf receptor kinase inhibitor
NZ617765B2 (en) Substituted pyridopyrazines as novel syk inhibitors
WO2025207620A1 (fr) Modulateurs d'akt1
WO2025188662A1 (fr) Modulateurs d'akt1
HK1190143B (en) Substituted pyridopyrazines as novel syk inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20141104

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/00 20060101ALI20141029BHEP

Ipc: A61P 35/00 20060101ALI20141029BHEP

Ipc: A61K 31/4985 20060101ALI20141029BHEP

Ipc: A61P 37/08 20060101ALI20141029BHEP

Ipc: A61K 31/553 20060101ALI20141029BHEP

Ipc: A61P 7/00 20060101ALI20141029BHEP

Ipc: A61P 35/02 20060101ALI20141029BHEP

Ipc: A61P 29/00 20060101ALI20141029BHEP

Ipc: C07D 471/04 20060101AFI20141029BHEP

Ipc: A61P 43/00 20060101ALI20141029BHEP

Ipc: A61K 31/5375 20060101ALI20141029BHEP

17Q First examination report despatched

Effective date: 20150929

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20161012

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HUTCHISON MEDIPHARMA LIMITED

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTG Intention to grant announced

Effective date: 20170321

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20170511

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 939805

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012038989

Country of ref document: DE

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20180139

Country of ref document: HR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20180124

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2718293

Country of ref document: PT

Date of ref document: 20180130

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20180123

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: LUCHS AND PARTNER AG PATENTANWAELTE, CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2657549

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180305

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20171025

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E015228

Country of ref document: EE

Effective date: 20180314

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20180139

Country of ref document: HR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20180400231

Country of ref document: GR

Effective date: 20180518

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012038989

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E037934

Country of ref document: HU

26N No opposition filed

Effective date: 20180726

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180139

Country of ref document: HR

Payment date: 20190521

Year of fee payment: 8

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180139

Country of ref document: HR

Payment date: 20200520

Year of fee payment: 9

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180139

Country of ref document: HR

Payment date: 20210519

Year of fee payment: 10

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 939805

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171025

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180139

Country of ref document: HR

Payment date: 20220525

Year of fee payment: 11

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180139

Country of ref document: HR

Payment date: 20230519

Year of fee payment: 12

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230518

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20230522

Year of fee payment: 12

Ref country code: MC

Payment date: 20230522

Year of fee payment: 12

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180139

Country of ref document: HR

Payment date: 20240522

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20240523

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240701

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E015228

Country of ref document: EE

Effective date: 20240630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240630

REG Reference to a national code

Ref country code: EE

Ref legal event code: TH4A

Ref document number: E015228

Country of ref document: EE

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180139

Country of ref document: HR

Payment date: 20250521

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20250625

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250627

Year of fee payment: 14

Ref country code: PL

Payment date: 20250521

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250627

Year of fee payment: 14

Ref country code: DK

Payment date: 20250625

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20250520

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RS

Payment date: 20250521

Year of fee payment: 14

Ref country code: IS

Payment date: 20250602

Year of fee payment: 14

Ref country code: NO

Payment date: 20250627

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20250610

Year of fee payment: 14

Ref country code: LU

Payment date: 20250627

Year of fee payment: 14

Ref country code: NL

Payment date: 20250626

Year of fee payment: 14

Ref country code: BE

Payment date: 20250627

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HR

Payment date: 20250521

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20250521

Year of fee payment: 14

Ref country code: LV

Payment date: 20250520

Year of fee payment: 14

PG2D Information on lapse in contracting state deleted

Ref country code: EE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250625

Year of fee payment: 14

Ref country code: EE

Payment date: 20250603

Year of fee payment: 14

Ref country code: HU

Payment date: 20250530

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20250520

Year of fee payment: 14

Ref country code: BG

Payment date: 20250610

Year of fee payment: 14

Ref country code: GR

Payment date: 20250626

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20250529

Year of fee payment: 14

Ref country code: AT

Payment date: 20250521

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20250526

Year of fee payment: 14

Ref country code: SK

Payment date: 20250521

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20250523

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20250627

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20250519

Year of fee payment: 14

Ref country code: SE

Payment date: 20250627

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250701

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20250619

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250701

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20250521

Year of fee payment: 14